Cancer Communications
indexed by SCI
BMC


Research highlight
Moving beyond hydroxychloroquine: the novel lysosomal autophagy inhibitor ROC-325 shows significant potential in preclinical studies
Trace M. Jones, Claudia Espitia, Wei Wang, Steffan T. Nawrocki & Jennifer S. Carew
Cancer Communications 2019 39: 72
[ Abstract ]    [ PDF Full-text ]    [ HTML Full-text ]     [ PubMed]   Epub: 11/9/2019   doi:10.1186/s40880-019-0418-0
Research highlight
Nuclear glycogenolysis modulates histone acetylation: a novel mechanism of epigenetic regulation in cancer
Xifeng Dong
Cancer Communications 2019 39: 71
[ Abstract ]    [ PDF Full-text ]    [ HTML Full-text ]     [ PubMed]   Epub: 11/9/2019   doi:10.1186/s40880-019-0420-6
Research highlight
CD137 expression in cancer cells: regulation and significance
Christophe Glorieux & Peng Huang
Cancer Communications 2019 39: 70
[ Abstract ]    [ PDF Full-text ]    [ HTML Full-text ]     [ PubMed]   Epub: 11/8/2019   doi:10.1186/s40880-019-0419-z
Study Protocol
The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)
Zhonghan Zhang, Fan Luo, Yang Zhang, Yuxiang Ma, Shaodong Hong, Yunpeng Yang, Wenfeng Fang, Yan Huang, Li Zhang & Hongyun Zhao
Cancer Communications 2019 39: 69
[ Abstract ]    [ PDF Full-text ]    [ HTML Full-text ]     [ PubMed]   Epub: 11/7/2019   doi:10.1186/s40880-019-0414-4
Original article
Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification
Zhi-Xia Yue, Tian-Yu Xing, Chao Gao, Shu-Guang Liu, Wen Zhao, Qian Zhao, Xi-Si Wang, Mei Jin & Xiao-Li Ma
Cancer Communications 2019 39: 68
[ Abstract ]    [ PDF Full-text ]    [ HTML Full-text ]     [ PubMed]   Epub: 11/4/2019   doi:10.1186/s40880-019-0409-1
Letter to the Editor
A case of EGFR mutation-positive lung adenocarcinoma in which the T790M allele fraction was increased by repeated EGFR-TKI treatment
Hideharu Kimura, Yoshiaki Amino, Hayato Koba, Yuichi Tambo, Noriyuki Ohkura, Johsuke Hara, Takashi Sone & Kazuo Kasahara
Cancer Communications 2019 39: 67
[ Abstract ]    [ PDF Full-text ]    [ HTML Full-text ]     [ PubMed]   Epub: 11/1/2019   doi:10.1186/s40880-019-0413-5
Original article
Laparoscopic versus open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a propensity score matching analysis
Wentao Zhou, Weiwei Jin, Dansong Wang, Chao Lu, Xuefeng Xu, Renchao Zhang, Tiantao Kuang, Yucheng Zhou, Wenchuan Wu, Dayong Jin, Yiping Mou & Wenhui Lou
Cancer Communications 2019 39: 66
[ Abstract ]    [ PDF Full-text ]    [ HTML Full-text ]     [ PubMed]   Epub: 10/28/2019   doi:10.1186/s40880-019-0410-8
Research highlight
S-1 plus docetaxel: a safe and effective chemotherapy regimen for stage III gastric cancer
Feiyu Diao, Wei Lai & Zhonghua Chu
Cancer Communications 2019 39: 65
[ Abstract ]    [ PDF Full-text ]    [ HTML Full-text ]     [ PubMed]   Epub: 10/26/2019   doi:10.1186/s40880-019-0408-2
Research highlight
Optimal sequencing of chemotherapy with chemoradiotherapy based on TNM stage classification and EBV DNA in locoregionally advanced nasopharyngeal carcinoma
Li-Ting Liu, Melvin L. K. Chua, Yungan Tao, Lin-Quan Tang & Hai-Qiang Mai
Cancer Communications 2019 39: 64
[ Abstract ]    [ PDF Full-text ]    [ HTML Full-text ]     [ PubMed]   Epub: 10/25/2019   doi:10.1186/s40880-019-0398-0
Research highlight
Targeting mitochondria as an anticancer strategy
Lanfeng Dong & Jiri Neuzil
Cancer Communications 2019 39: 63
[ Abstract ]    [ PDF Full-text ]    [ HTML Full-text ]     [ PubMed]   Epub: 10/25/2019   doi:10.1186/s40880-019-0412-6

<<    Page 2 of 24  >>    




CJC Wechat 微信公众号


 

Editorial Manager


CC adopts ScholarOne Manuscripts to manage its submissions from Nov.1, 2019

 Submission Guidelines  

 

Reference style for  

 EndNote,
 Reference Manager



Editorial Manager


 

Year:

 

Month:

Advanced search

Subscription


CC is now published by Wiley

© Cancer Communications

651 Dongfeng Road East, Guangzhou 510060, P. R. China